• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Intarcia raises another $215m to support its ITCA 650 drug pump

Intarcia raises another $215m to support its ITCA 650 drug pump

September 15, 2016 By Fink Densford

Intarcia TherapeuticsIntarcia Therapeutics said today that it raised $215 million in a new round of financing to back its ITCA 650 implantable drug pump, designed for treating Type II diabetes, which is slated to launch in late 2017.

The Cambridge, Mass.-based company said it expects a “larger 2nd close with additional top-tier investors” in the 4th quarter. Intarcia is looking to raise up to $600 million by the end of the year to support the approval and launch of the device, according to a regulatory filing.

The ITCA 650 pump is a matchstick-sized, miniature osmotic pump designed to deliver the drug exenatide for 1 year. It uses technology from the company’s already-cleared Medici system.

“Intarcia remains focused on building an innovative and important company in the chronic disease space – one dedicated to addressing serious unmet needs by disrupting the shortcomings of the pill and injection model in chronic disease management. Ultimately, our goal is to open up a new pathway of delivering once or twice yearly medicines that fundamentally hold the potential to transform therapeutic and economic outcomes over time for millions of patients, and the healthcare system overall. At our core, our proprietary Medici drug delivery system does this by stabilizing and optimizing the potential of the medicines we develop, enabling the medicine to be delivered just once or twice yearly, and by addressing the massive behavioral challenge of non-adherence with pills and injections that currently impacts the majority of patients in every chronic disease we face. It’s an exciting prospect to create a potentially critical new pathway of delivering important medicines for some of the largest and costliest chronic diseases in the world, where very little progress in overall outcomes has been made. We’re thrilled with the quality and strength of the shareholder base we’re continuing to build for our future, and the ability we collectively have to deliver on our purpose and our mission – improving the lives of millions of patients,” chairman, president & CEO Kurt Graves said in a press release.

The cash will also support “several novel pipeline programs” for major chronic diseases such as diabetes, obesity, auto-immune disorders and inflammation, the company said.

Intarcia launched the Medici system in June. Earlier in the month, the company and pharmaceuticals maker Numab said they logged several milestones in their joint project to develop a drug-device combination for treating inflammatory and autoimmune diseases.

Filed Under: Diabetes, Drug Pumps, Funding Roundup, Wall Street Beat Tagged With: Intarcia Therapeutics

In case you missed it

  • FDA clears Neurolief’s noninvasive neuromod tech to treat migraines
  • Could this hydrogel repair a broken heart?
  • Virta Health touts study of treatment preventing progression to Type 2 diabetes
  • Philips, DiA partner on AI-based applications for ultrasound
  • Cook Medical wins FDA breakthrough device designation for next-gen endovascular graft
  • FDA grants breakthrough nod to Anuncia’s cerebral spinal fluid treatment
  • Varian CEO Dow Wilson to retire after merger with Siemens Healthineers
  • Medtronic touts results of cardiac resynchronization therapy trial
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
  • Abbott researchers help discover a clue to an HIV cure
  • Q BioMed wins federal contract for bone cancer drug
  • Report: Biden to announce partnership for Merck to make J&J’s COVID-19 vaccine
  • FDA accepts New Drug Application for Eyenovia pupil dilation tech
  • Axonics, Micro Systems Technologies partners to make rechargeable SNM device
  • Component Testing & Analysis: How to Gain Deeper Insights with a Universal Testing System
  • SeaSpine ticks up on 6.2% sales growth in Q4, reports losses
  • Boston Scientific completes Preventice buy, divests BTG Pharmaceutical business

RSS From Medical Design & Outsourcing

  • Pharma’s been slow to adopt Industry 4.0 — but that could change
    The pharma industry has been relatively slow to embrace concepts such as Industry 4.0, but COVID-19 is serving as a catalyst for sweeping changes within the industry. The philosophy has roots in a German framework that prioritizes digitization to drive manufacturing efficiency, promising that cyber-physical systems will usher in the next industrial revolution. The Industry… […]
  • Ambu single-use endoscope wins Frost & Sullivan innovation award
    Frost & Sullivan today announced that it awarded Ambu with a 2021 Global New Product Innovation Award. Ambu received the award for its single-use flexible endoscopes that are designed to make the devices safe, affordable and accessible. It has aView and aBox all-in-one video displays that eliminate the traditional video endoscopy tower size and expense to be… […]
  • Could this hydrogel repair a broken heart?
    European researchers have developed an injectable hydrogel that could help repair and prevent further heart muscle damage after a heart attack. The therapeutic effect of multiple injections of this hydrogel into the cardiac tissue was assessed during the first preclinical study of its kind, demonstrating its efficacy for cardiac tissue remodeling following a heart attack,… […]
  • How EtO plants can avoid lawsuits, cope with stricter regulation
    If EtO industry actors take certain targeted steps now, they can minimize legal exposure, more efficiently manage litigation and be better situated for compliance once new federal regulations are established. Karen Cullinane, Goldberg Segalla The use of ethylene oxide (EtO) to sterilize medical devices came under renewed scrutiny after the Environmental Protection Agency concluded in… […]
  • FDA authorizes Q-Collar to help protect athletes’ brains
    The FDA announced today that it authorized the Q-Collar made by Q30 Sports Science for protecting the brain during sports activities. Q30 Sports Science’s Q-Collar is a C-shaped collar worn around the neck designed to apply compressive force to the neck and increase blood volume to help reduce movement of the brain within the cranial… […]
  • The top 7 medtech CEO quotes on COVID-19, one year later
    The latest earnings season has provided insights into the future of medtech in the COVID-19 landscape and what certain sectors are seeing as vaccines start to roll out. Since the start of the pandemic, 113.1 million COVID-19 cases have been reported worldwide, according to Johns Hopkins University School of Medicine. The U.S. leads the world… […]
  • Pfizer wins FDA nod to store COVID vaccine at normal freezer temps
    The FDA announced today that it is allowing undiluted, frozen vials of the Pfizer-BioNTech COVID-19 vaccine to be transported and stored for up to two weeks at conventional temperatures commonly found in pharmaceutical freezers. The decision should allow for wider distribution of the vaccine to sites that do not have ultra-low temperature freezers. Pfizer asked… […]
  • 8 drug delivery innovations you need to know
    The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the… […]
  • Hoffer Plastics gains MedAccred certification again
    Injection molding company Hoffer Plastics (South Elgin, Ill.) announced that it has received the MedAccred re-certification from not-for-profit medtech audit provider MedAccred. MedAccred is a supply-chain oversight program of the Performance Review Institute. It conducts critical-process audits for its member OEMs to ensure their suppliers adhere to global regulations and requirements, and helps reduce the number… […]
  • UK passes post-Brexit medical device regulation
    The U.K. has enacted a new law governing medical devices and drugs, with a focus on patient safety. The Medicines and Medical Devices Act, introduced in July 2020, establishes the position of commissioner for patient safety to respond to public and patient complaints and concerns about drugs and medical devices. The law was necessitated by… […]
  • Integrated Polymer Solutions acquires IRP Group
    Integrated Polymer Solutions (“IPS”), a portfolio company of Arcline Investment Management, announced this week that it has acquired IRP Group. IRP designs and manufacturers elastomeric sealing components from its facilities in Southern California. Founded in 1999, the company is focused on the Class I and II medical device market as well as the aerospace &… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS